Waqar Haque

Response rates and pathologic complete response by breast cancer molecular subtype following neoadjuvant chemotherapy

Waqar Haque, Vivek Verma, Sandra S. Hatch et al. · Breast Cancer Research and Treatment · 2018 · 388 citations

Medicine, Oncology, Breast Oncology +16

Phase II Trial of Cetuximab, Gemcitabine, and Oxaliplatin Followed by Chemoradiation With Cetuximab for Locally Advanced (T4) Pancreatic Adenocarcinoma: Correlation of <i>Smad4(Dpc4)</i> Immunostaining With Pattern of Disease Progression

Christopher H. Crane, Gauri R. Varadhachary, John S. Yordy et al. · Journal of Clinical Oncology · 2011 · 287 citations · Full text

Medicine, Oncology, Radiation Oncology +17

Racial and Socioeconomic Disparities in the Delivery of Immunotherapy for Metastatic Melanoma in the United States

Waqar Haque, Vivek Verma, E. Brian Butler et al. · Journal of Immunotherapy · 2019 · 80 citations

Medicine, Health Policy, Oncology +15

Racial and Insurance-related Disparities in Delivery of Immunotherapy-type Compounds in the United States

Vivek Verma, Waqar Haque, Taylor R. Cushman et al. · Journal of Immunotherapy · 2019 · 66 citations

Public Health, Oncology, Epidemiology +16

Comparison of outcomes between metaplastic and triple-negative breast cancer patients

Praveen Polamraju, Waqar Haque, Kevin Cao et al. · The Breast · 2019 · 51 citations · Full text

Medicine, Oncology, Breast Oncology +13